| Nome |
# |
|
On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites, file e3835328-1b27-15e8-e053-a505fe0a3de9
|
565
|
|
Muscle alterations are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis, file e3835324-4903-15e8-e053-a505fe0a3de9
|
541
|
|
Hepatic encephalopathy in patients with non-cirrhotic portal hypertension: Description, prevalence and risk factors, file e3835316-630a-15e8-e053-a505fe0a3de9
|
437
|
|
Natural history of patients with non cirrhotic portal hypertension: Comparison with patients with compensated cirrhosis, file e383531a-000e-15e8-e053-a505fe0a3de9
|
406
|
|
Cognitive impairment predicts the occurrence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt, file e3835316-6224-15e8-e053-a505fe0a3de9
|
347
|
|
No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt, file e383531e-8520-15e8-e053-a505fe0a3de9
|
323
|
|
The modification of splenic stiffness on acoustic radiation force impulse parallels the variation of portal pressure induced by transjugular intrahepatic portosystemic shunt, file e3835319-f7d6-15e8-e053-a505fe0a3de9
|
282
|
|
Proton pump inhibitors are associated with minimal and overt hepatic encephalopathy and increased mortality in patients with cirrhosis, file e3835322-16ab-15e8-e053-a505fe0a3de9
|
232
|
|
Portal Hypertension Related to Schistosomiasis Treated with a Transjugular Intrahepatic Portosystemic Shunt, file e383531e-b8b7-15e8-e053-a505fe0a3de9
|
191
|
|
Sarcopenia and cognitive impairment in liver cirrhosis: a viewpoint on the clinical impact of minimal hepatic encephalopathy, file e3835324-429c-15e8-e053-a505fe0a3de9
|
158
|
|
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9), file e383532d-d0e2-15e8-e053-a505fe0a3de9
|
135
|
|
Hepatic Encephalopathy Expands the Predictivity of Meld in Liver Transplant Setting: Evidence by Means of two Independent Cohorts, file e3835316-8d3e-15e8-e053-a505fe0a3de9
|
126
|
|
Poliprotect vs omeprazole in the relief of heartburn, epigastric pain and burning in patients without erosive esophagitis and gastro-duodenal lesions. A randomized, controlled trial, file 6aa22998-a7b5-4c5d-bd73-1e69f63dbd5e
|
119
|
|
AISF-SIMTI Position Paper: The appropriate use of albumin in patients with liver cirrhosis, file e383531e-b793-15e8-e053-a505fe0a3de9
|
115
|
|
A cost analysis of a broad-spectrum antibiotic therapy in the empirical treatment of health care-associated infections in cirrhotic patients, file e3835317-ff8b-15e8-e053-a505fe0a3de9
|
112
|
|
Albumin infusion in cirrhotic patients with infections other than spontaneous bacterial peritonitis: End of the story?, file e383531e-a6cf-15e8-e053-a505fe0a3de9
|
110
|
|
Is porto sinusoidal vascular disease to be actively searched in patients with portal vein thrombosis?, file e3835323-1cb9-15e8-e053-a505fe0a3de9
|
107
|
|
Idiopathic noncirrhotic portal hypertension: current perspectives, file e3835315-2329-15e8-e053-a505fe0a3de9
|
104
|
|
The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey, file e3835314-0f2b-15e8-e053-a505fe0a3de9
|
100
|
|
Quality of life in patients with minimal hepatic encephalopathy, file e3835321-ce47-15e8-e053-a505fe0a3de9
|
78
|
|
Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms, file e3835327-b103-15e8-e053-a505fe0a3de9
|
71
|
|
Beta-blokers in patients with cirrhosis and infection: don't blame too soon., file e3835313-e19d-15e8-e053-a505fe0a3de9
|
64
|
|
The burden of minimal hepatic encephalopathy: from diagnosis to therapeutic strategies, file e3835327-c4dc-15e8-e053-a505fe0a3de9
|
62
|
|
Radiological Intervention for Shunt Related Encephalopathy, file e3835327-c82c-15e8-e053-a505fe0a3de9
|
60
|
|
Oxidative stress in the pathogenesis of antiphospholipid syndrome. Implications for the atherothrombotic process, file e383532e-dd26-15e8-e053-a505fe0a3de9
|
60
|
|
Ammonia and the muscle: an emerging point of view on hepatic encephalopathy, file e383532e-18e5-15e8-e053-a505fe0a3de9
|
54
|
|
Small hepatic veins Budd-Chiari syndrome and paroxysmal nocturnal hemoglobinuria - The association of two rare entities: a case report, file e3835327-239e-15e8-e053-a505fe0a3de9
|
53
|
|
Old and new precipitants in hepatic encephalopathy: a new look at a field in continuous evolution, file 0c582353-79ec-4812-9396-913288d422b2
|
23
|
|
Nutritional status: its influence on the outcome of patients undergoing liver transplantation, file e3835311-c637-15e8-e053-a505fe0a3de9
|
19
|
|
Neurological and psychiatric effects of hepatitis C virus infection, file 8328c0af-0751-4995-ab86-321b3f1ca576
|
17
|
|
High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: A case-control study, file e3835311-c82b-15e8-e053-a505fe0a3de9
|
16
|
|
Cirrhotic patients are at risk for health care-associated bacterial infections., file e3835311-c98a-15e8-e053-a505fe0a3de9
|
14
|
|
Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts, file e3835311-ee7c-15e8-e053-a505fe0a3de9
|
14
|
|
Depression, anxiety and alexithymia symptoms are major determinants of health related quality of life (HRQoL) in cirrhotic patients, file e3835312-4927-15e8-e053-a505fe0a3de9
|
14
|
|
Hepatic encephalopathy: diagnosis and management, file e3835329-9fc6-15e8-e053-a505fe0a3de9
|
13
|
|
Polytetrafluoroethylene-covered nitinol stent-graft for transjugular intrahepatic portosystemic shunt creation: 3-year experience., file e3835311-e56d-15e8-e053-a505fe0a3de9
|
12
|
|
Nutrition assessment and management in patients with cirrhosis and cognitive impairment: a comprehensive review of literature, file e383532e-d60c-15e8-e053-a505fe0a3de9
|
12
|
|
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial, file 5e5fc3d8-1ae6-465f-804e-5597886ee56b
|
11
|
|
Minimal hepatic encephalopathy and sleep disorders in patients with cirrhosis. Which comes first?, file e3835327-b77b-15e8-e053-a505fe0a3de9
|
11
|
|
An empirical broad spectrum antibiotic therapy in Healthcare-Associated infections improves survival in cirrhotics. A randomized trial, file e3835314-1c12-15e8-e053-a505fe0a3de9
|
9
|
|
Editorial: Infections and hepatic encephalopathy–does the chicken or the egg come FIRST? A novel perspective at the horizon, file e383532e-06d0-15e8-e053-a505fe0a3de9
|
9
|
|
Predictive Factors of Outcome After Liver Transplantation in Patients With Cirrhosis and Hepatocellular Carcinoma, file e3835312-20c3-15e8-e053-a505fe0a3de9
|
8
|
|
Cognitive impairement in non-cirrhotic portal hypertension: highlights on physiopathology, diagnosis and management, file e383532d-8a9b-15e8-e053-a505fe0a3de9
|
8
|
|
Management of Hepatic Encephalopathy as an
Inpatient, file e3835313-0152-15e8-e053-a505fe0a3de9
|
7
|
|
Survival at 2 years among liver cirrhotic patients is influenced by left atrial volume and left ventricular mass, file e383531a-564b-15e8-e053-a505fe0a3de9
|
7
|
|
Small hepatic veins Budd-Chiari syndrome, file e3835321-dd6a-15e8-e053-a505fe0a3de9
|
7
|
|
Hemostatic balance in patients with liver cirrhosis. report of a consensus conference, file e383532a-8b7b-15e8-e053-a505fe0a3de9
|
7
|
|
The management of hepatic encephalopathy from ward to domiciliary care: current evidence and gray areas, file afbe809f-4b09-4b6e-992e-44bfeb244136
|
5
|
|
Transjugular intrahepatic portosystemic shunt (tips) versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis. A randomized multicenter trial., file e3835311-b7f7-15e8-e053-a505fe0a3de9
|
5
|
|
Idiopathic non cirrhotic portal hypertension and spleno-portal axis abnormalities in patients with severe primary antibody deficiencies., file e3835311-d379-15e8-e053-a505fe0a3de9
|
5
|
|
Improvement of nutritional status in malnourished cirrhotic patients one year after liver transplantation, file e3835311-df4b-15e8-e053-a505fe0a3de9
|
5
|
|
PPIs in cirrhosis: more evidences for a careful prescription!, file e3835322-209e-15e8-e053-a505fe0a3de9
|
5
|
|
Spontaneous porto-systemic shunts in liver cirrhosis. Clinical and therapeutical aspects, file e383532c-a7f1-15e8-e053-a505fe0a3de9
|
5
|
|
Clotting activation after transjugular intrahepatic portosystemic stent shunt, file e3835311-7e92-15e8-e053-a505fe0a3de9
|
4
|
|
Low-grade endotoxemia and platelet activation in cirrhosis, file e3835317-02f6-15e8-e053-a505fe0a3de9
|
4
|
|
Gut liver muscle brain axis. A comprehensive viewpoint on prognosis in cirrhosis, file e383532e-be17-15e8-e053-a505fe0a3de9
|
4
|
|
The application of pancreatitis activity score system in clinical practice: an italian experience, file e8c2d0fb-9857-42e9-9db5-7fd4a78b1f01
|
4
|
|
Minimal hepatic encephalopathy affects daily life of cirrhotic patients: a viewpoint on clinical consequences and therapeutic opportunities, file afb24068-21e2-4851-ab65-455a82838867
|
3
|
|
Comment to: “TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis.”, file d3311e52-96bf-4c6c-ab87-006b3d55ae87
|
3
|
|
Impaired hepatic handling and processing of lysophosphatidylcholine in rats with liver cirrhosis., file e3835311-501c-15e8-e053-a505fe0a3de9
|
3
|
|
Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis, file e383531d-b391-15e8-e053-a505fe0a3de9
|
3
|
|
Prevalence and impact of sarcopenia in non-cirrhotic portal hypertension, file e3835321-cdcc-15e8-e053-a505fe0a3de9
|
3
|
|
Incidence of portal hypertension in patients exposed to oxaliplatin, file e3835324-4a61-15e8-e053-a505fe0a3de9
|
3
|
|
Hepatic encephalopathy in the 21st century. Still an emerging topic, file e3835329-5c5d-15e8-e053-a505fe0a3de9
|
3
|
|
Porto-sinusoidal vascular disorder (PSVD): application of new diagnostic criteria in a multicenter cohort of patients, file 3a997ccb-5f6f-46eb-882b-5bd9f2a73b38
|
2
|
|
Transjugular intrahepatic portosystemic shunt placement: effects on nutritional status in cirrhotic patients, file 3f195305-bb9a-45a1-b974-930d003b89ab
|
2
|
|
Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis, file 9729167d-355b-4e7c-8d6f-38a12dcabeec
|
2
|
|
Application of ultrasonography-elastography score to suspect porto-sinusoidal vascular disease in patients with portal vein thrombosis, file c368443d-f854-4f44-b816-dad1aafe81c8
|
2
|
|
Determinants of prognosis in cirrhosis: a new outlook, file c497e172-75c2-4a2e-8ecd-3903eb803e83
|
2
|
|
Evidence of Persistent Cognitive Impairment After Resolution of Overt Hepatic Encephalopathy, file e3835314-0f9c-15e8-e053-a505fe0a3de9
|
2
|
|
Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt, file e3835315-71b6-15e8-e053-a505fe0a3de9
|
2
|
|
Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial, file e3835315-b0d8-15e8-e053-a505fe0a3de9
|
2
|
|
The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS, file e3835321-cad9-15e8-e053-a505fe0a3de9
|
2
|
|
The animal naming test: an easy tool for the assessment of hepatic encephalopathy, file e3835321-eac7-15e8-e053-a505fe0a3de9
|
2
|
|
The additive value of sarcopenia, myosteatosis and hepatic encephalopathy in the predictivity of model for end-stage liver disease, file e3835324-5f86-15e8-e053-a505fe0a3de9
|
2
|
|
Clinical management of type C hepatic encephalopathy, file e3835327-ae07-15e8-e053-a505fe0a3de9
|
2
|
|
Relevance of spontaneous portosystemic shunts detected with CT in patients with cirrhosis, file e383532c-0d67-15e8-e053-a505fe0a3de9
|
2
|
|
Risk factors for hepatic encephalopathy and mortality in cirrhosis: the role of cognitive impairment, muscle alterations and shunts: predictors of HE, file e383532e-03f4-15e8-e053-a505fe0a3de9
|
2
|
|
Association between gut-derived endotoxins and porto-sinusoidal vascular disorder with portal hypertension, file eab437e4-c84d-47e7-bb8c-2f4050048c1c
|
2
|
|
Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study, file 052cc3f2-d317-4ad9-acb0-e00486c325d4
|
1
|
|
Primary prophylaxis of overt hepatic encephalopathy: is it time to consider it?, file 07f9da71-648a-4dc7-a420-33fb3711a69c
|
1
|
|
Albumin for cognitive impairment after TIPS: a road to be explored, file 4ffcc379-f8a2-4ed3-b6bc-6984629a0e2b
|
1
|
|
Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study, file e3835311-c832-15e8-e053-a505fe0a3de9
|
1
|
|
NADPH oxidase-mediated platelet isoprostane over-production in cirrhotic patients: implication for platelet activation, file e3835311-dfe2-15e8-e053-a505fe0a3de9
|
1
|
|
Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease, file e3835312-20a3-15e8-e053-a505fe0a3de9
|
1
|
|
Vascular disorders of the liver: recommendations from the Italian Association for the Study of the Liver (AISF) ad hoc committee., file e3835312-21f5-15e8-e053-a505fe0a3de9
|
1
|
|
Diagnosis, treatment and survival of patients with hepatorenal syndrome: A survey on daily medical practice, file e3835312-21f6-15e8-e053-a505fe0a3de9
|
1
|
|
The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis., file e3835314-0f94-15e8-e053-a505fe0a3de9
|
1
|
|
A Simplified Psychometric Evaluation for the Diagnosis of Minimal Hepatic Encephalopathy, file e3835314-0ffc-15e8-e053-a505fe0a3de9
|
1
|
|
A low muscle mass increases mortality in compensated cirrhotic patients with sepsis, file e3835319-e765-15e8-e053-a505fe0a3de9
|
1
|
|
I test con risposte a scelta multipla nel percorso formativo del medico, file e383531c-0e4b-15e8-e053-a505fe0a3de9
|
1
|
|
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial, file e383531e-ad4e-15e8-e053-a505fe0a3de9
|
1
|
|
Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF), file e3835322-16a2-15e8-e053-a505fe0a3de9
|
1
|
|
May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?, file e3835322-2cd2-15e8-e053-a505fe0a3de9
|
1
|
|
Erectile dysfunction in patients with liver cirrhosis, file e3835324-26a0-15e8-e053-a505fe0a3de9
|
1
|
|
How to design a multicenter clinical trial in hepatic encephalopathy, file e3835324-48b3-15e8-e053-a505fe0a3de9
|
1
|
|
Prediction of hepatic encephalopathy: Why disregard well-known risk factors?, file e3835327-ca12-15e8-e053-a505fe0a3de9
|
1
|
|
Episodic precipitant-induced hepatic encephalopathy treatment: the ideal trial is still lacking, file e383532e-36ef-15e8-e053-a505fe0a3de9
|
1
|
|
Albumin for cognitive impairment after TIPS: a road to be explored, file f8195017-b58b-466b-a691-1fd3e3c48250
|
1
|
| Totale |
5.367 |